AAAAAA
Results:
1-21
|
Results: 21
Authors:
Ravaud, A
Borner, M
Schellens, JHM
Geoffrois, L
Schoffski, BP
Kroon, K
Wanders, J
Hanauske, AR
Fumoleau, P
Citation: A. Ravaud et al., UFT and leucovorin in first-line chemotherapy for patients with metastaticgastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial, EUR J CANC, 37(13), 2001, pp. 1642-1647
Authors:
Maes, M
Capuron, L
Ravaud, A
Gualde, N
Bosmans, E
Egyed, B
Dantzer, R
Neveu, PJ
Citation: M. Maes et al., Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy, NEUROPSYCH, 24(2), 2001, pp. 130-140
Authors:
Capuron, L
Ravaud, A
Gualde, N
Bosmans, E
Dantzer, R
Maes, M
Neveu, PJ
Citation: L. Capuron et al., Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy, PSYCHONEURO, 26(8), 2001, pp. 797-808
Authors:
Capuron, L
Ravaud, A
Dantzer, R
Citation: L. Capuron et al., Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients, PSYCHOS MED, 63(3), 2001, pp. 376-386
Authors:
Ravaud, A
Citation: A. Ravaud, Cell therapy for solid tumors, B CANCER, 88(1), 2001, pp. 91-100
Authors:
Negrier, S
Fervers, B
Bailly, C
Beckendorf, V
Cupissol, D
Dore, JF
Garbay, JR
Vilmer, C
Borel, C
Boulier, N
Cabarrot, E
Carrie, C
Chevreau, C
de Cislain, C
Delaunay, MM
Depardieu, C
Dubois, JB
Escande, MC
Fraisse, J
Parache, RM
Philip, T
Ravaud, A
Sancho-Garnier, H
Spatz, A
Autier, P
Bonnetblanc, JM
de Raucourt, S
Dreno, B
Gouttebel, MC
Grange, F
Guillot, B
Khayat, D
Lehmann, M
Leroy, D
Regal, R
Revuz, J
Saiag, P
Schmutz, JL
Truchetet, F
Vuillemin, P
Citation: S. Negrier et al., Standards, options and guidelines for caring for patients with cutaneous melanomas, PRESSE MED, 29(23), 2000, pp. 1317-1326
Authors:
Capuron, L
Ravaud, A
Dantzer, R
Citation: L. Capuron et al., Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy, J CL ONCOL, 18(10), 2000, pp. 2143-2151
Authors:
Ravaud, A
Citation: A. Ravaud, Taxane-induced glaucoma - Reply, LANCET, 355(9203), 2000, pp. 577-577
Authors:
Coulon, V
Ravaud, A
Gaston, R
Delaunay, MM
Pariente, JL
Verdier, D
Scrivante, V
Gualde, N
Citation: V. Coulon et al., In vitro immunization of patient T cells with autologous bone marrow antigen presenting cells pulsed with tumor lysates, INT J CANC, 88(5), 2000, pp. 783-790
Authors:
Ravaud, A
Debled, M
Citation: A. Ravaud et M. Debled, Present achievements in the medical treatment of metastatic renal cell carcinoma, CR R ONC H, 31(1), 1999, pp. 77-87
Authors:
Cure, H
Souteyrand, P
Ouabdesselam, R
Roche, H
Ravaud, A
D'incan, M
Viens, P
Fargeot, P
Lentz, MA
Fumoleau, P
Hanauske, A
Chollet, P
Citation: H. Cure et al., Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- orsecond-line treatment in advanced malignant melanoma: a trial of the EORTCClinical Studies Group, MELANOMA RE, 9(6), 1999, pp. 607-610
Authors:
Ravaud, A
Borner, M
Schellens, JHM
Geoffrois, L
Schoffski, P
Wanders, J
Hanauske, AR
Citation: A. Ravaud et al., UFT and oral calcium folinate as first-line chemotherapy for metastatic gastric cancer, ONCOLOGY-NY, 13(7), 1999, pp. 61-63
Authors:
Ray-Coquard, I
Le Cesne, A
Rubio, MT
Mermet, J
Maugard, C
Ravaud, A
Chevreau, C
Sebban, C
Bachelot, T
Biron, P
Blay, JY
Citation: I. Ray-coquard et al., Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens, J CL ONCOL, 17(9), 1999, pp. 2840-2846
Authors:
Ravaud, A
Bui, BN
Citation: A. Ravaud et Bn. Bui, Granulocyte-macrophage colony-stimulating factor in established febrile neutropenia - In reply, J CL ONCOL, 17(9), 1999, pp. 3002-3002
Authors:
Escudier, B
Chevreau, C
Lasset, C
Douillard, JY
Ravaud, A
Fabbro, M
Caty, A
Rossi, JF
Viens, P
Bergerat, JP
Savary, J
Negrier, S
Citation: B. Escudier et al., Cytokines in metastatic renal cell carcinoma: Is it useful to switch to interleukin-2 or interferon after failure of a first treatment?, J CL ONCOL, 17(7), 1999, pp. 2039-2043
Authors:
Ravaud, A
Bui, BN
Citation: A. Ravaud et Bn. Bui, Misleading title and abstract in recent granulocyte-macrophage colony-stimulating factor trial - Reply, J CL ONCOL, 17(5), 1999, pp. 1645-1645
Authors:
Ravaud, A
Bui, BN
Citation: A. Ravaud et Bn. Bui, Granulocyte-macrophage colony-stimulating factor in established febrile neutropenia - Reply (vol 17, pg 3002, 1999), J CL ONCOL, 17(12), 1999, pp. 3860-3860
Authors:
Fabre-Guillevin, E
Tchen, N
Anibali-Charpiat, MF
Calluaud, L
Ravaud, A
Citation: E. Fabre-guillevin et al., Taxane-induced glaucoma, LANCET, 354(9185), 1999, pp. 1181-1182
Authors:
Capuron, L
Ravaud, A
Citation: L. Capuron et A. Ravaud, More on the depressive effects of interferon alfa - Reply, N ENG J MED, 341(11), 1999, pp. 849-850
Authors:
Capuron, L
Ravaud, A
Citation: L. Capuron et A. Ravaud, Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state, N ENG J MED, 340(17), 1999, pp. 1370-1370
Authors:
Ravaud, A
Bedane, C
Geoffrois, L
Lesimple, T
Delaunay, M
Citation: A. Ravaud et al., Toxicity and feasibility of adjuvant high dose interferon alpha-2b in patients with melanoma in clinical oncologic practice, BR J CANC, 80(11), 1999, pp. 1767-1769
Risultati:
1-21
|